Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)
NCT06897358Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Feb 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of leniolisib in common variable immunodeficiency (CVID), sponsored by Pharming Group. Started Feb 2025; status: completed.
02
Drugs
leniolisib
03
Conditions
common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on NCT06897358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897358.